205 related articles for article (PubMed ID: 36720762)
1. How I treat recurrent pediatric high-grade glioma (pHGG): a Europe-wide survey study.
Perwein T; Giese B; Nussbaumer G; von Bueren AO; van Buiren M; Benesch M; Kramm CM
J Neurooncol; 2023 Feb; 161(3):525-538. PubMed ID: 36720762
[TBL] [Abstract][Full Text] [Related]
2. Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma.
Rosenberg T; Yeo KK; Mauguen A; Alexandrescu S; Prabhu SP; Tsai JW; Malinowski S; Joshirao M; Parikh K; Farouk Sait S; Rosenblum MK; Benhamida JK; Michaiel G; Tran HN; Dahiya S; Kachurak K; Friedman GK; Krystal JI; Huang MA; Margol AS; Wright KD; Aguilera D; MacDonald TJ; Chi SN; Karajannis MA
Neuro Oncol; 2022 Nov; 24(11):1964-1975. PubMed ID: 35397478
[TBL] [Abstract][Full Text] [Related]
3. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
[TBL] [Abstract][Full Text] [Related]
4. Molecular Genetics and Targeted Therapies for Paediatric High-grade Glioma.
Rallis KS; George AM; Wozniak AM; Bigogno CM; Chow B; Hanrahan JG; Sideris M
Cancer Genomics Proteomics; 2022; 19(4):390-414. PubMed ID: 35732328
[TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
6. A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas.
Dixit KS; Sachdev S; Amidei C; Kumthekar P; Kruser TJ; Gondi V; Grimm S; Lukas RV; Nicholas MK; Chmura SJ; Fought AJ; Mehta M; Raizer JJ
J Neurooncol; 2021 Dec; 155(3):297-306. PubMed ID: 34689306
[TBL] [Abstract][Full Text] [Related]
7. Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma.
Bergman D; Modh A; Schultz L; Snyder J; Mikkelsen T; Shah M; Ryu S; Siddiqui MS; Walbert T
J Neurooncol; 2020 Jun; 148(2):353-361. PubMed ID: 32444980
[TBL] [Abstract][Full Text] [Related]
8. Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.
Crotty EE; Leary SES; Geyer JR; Olson JM; Millard NE; Sato AA; Ermoian RP; Cole BL; Lockwood CM; Paulson VA; Browd SR; Ellenbogen RG; Hauptman JS; Lee A; Ojemann JG; Vitanza NA
J Neurooncol; 2020 Jul; 148(3):607-617. PubMed ID: 32556862
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
Palmer JD; Bhamidipati D; Song A; Eldredge-Hindy HB; Siglin J; Dan TD; Champ CE; Zhang I; Bar-Ad V; Kim L; Glass J; Evans JJ; Andrews DW; Werner-Wasik M; Shi W
J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159
[TBL] [Abstract][Full Text] [Related]
10. Treatment of high-grade glioma in children and adolescents.
MacDonald TJ; Aguilera D; Kramm CM
Neuro Oncol; 2011 Oct; 13(10):1049-58. PubMed ID: 21784756
[TBL] [Abstract][Full Text] [Related]
11. Hemispherical Pediatric High-Grade Glioma: Molecular Basis and Therapeutic Opportunities.
Haase S; Nuñez FM; Gauss JC; Thompson S; Brumley E; Lowenstein P; Castro MG
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348922
[TBL] [Abstract][Full Text] [Related]
12. Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas.
Lazow MA; Hoffman L; Schafer A; Osorio DS; Boué DR; Rush S; Wright E; Lane A; DeWire-Schottmiller MD; Smolarek T; Sipple J; Taggert H; Reuss J; Salloum R; Hummel TR; de Blank P; Pillay-Smiley N; Sutton ME; Asher A; Stevenson CB; Drissi R; Finlay JL; Fouladi M; Fuller C
Acta Neuropathol Commun; 2020 Nov; 8(1):182. PubMed ID: 33153497
[TBL] [Abstract][Full Text] [Related]
13. Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial.
Mackay A; Burford A; Molinari V; Jones DTW; Izquierdo E; Brouwer-Visser J; Giangaspero F; Haberler C; Pietsch T; Jacques TS; Figarella-Branger D; Rodriguez D; Morgan PS; Raman P; Waanders AJ; Resnick AC; Massimino M; Garrè ML; Smith H; Capper D; Pfister SM; Würdinger T; Tam R; Garcia J; Thakur MD; Vassal G; Grill J; Jaspan T; Varlet P; Jones C
Cancer Cell; 2018 May; 33(5):829-842.e5. PubMed ID: 29763623
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
Peters KB; Lipp ES; Miller E; Herndon JE; McSherry F; Desjardins A; Reardon DA; Friedman HS
J Neurooncol; 2018 Apr; 137(2):349-356. PubMed ID: 29264836
[TBL] [Abstract][Full Text] [Related]
15. Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review.
Kulinich DP; Sheppard JP; Nguyen T; Kondajji AM; Unterberger A; Duong C; Enomoto A; Patel K; Yang I
Acta Neurochir (Wien); 2021 Jul; 163(7):1921-1934. PubMed ID: 33796887
[TBL] [Abstract][Full Text] [Related]
16. Challenging the indiscriminate use of temozolomide in pediatric high-grade gliomas: A review of past, current, and emerging therapies.
Guerra-García P; Marshall LV; Cockle JV; Ramachandran PV; Saran FH; Jones C; Carceller F
Pediatr Blood Cancer; 2020 Jan; 67(1):e28011. PubMed ID: 31617673
[TBL] [Abstract][Full Text] [Related]
17. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.
Mistry M; Zhukova N; Merico D; Rakopoulos P; Krishnatry R; Shago M; Stavropoulos J; Alon N; Pole JD; Ray PN; Navickiene V; Mangerel J; Remke M; Buczkowicz P; Ramaswamy V; Guerreiro Stucklin A; Li M; Young EJ; Zhang C; Castelo-Branco P; Bakry D; Laughlin S; Shlien A; Chan J; Ligon KL; Rutka JT; Dirks PB; Taylor MD; Greenberg M; Malkin D; Huang A; Bouffet E; Hawkins CE; Tabori U
J Clin Oncol; 2015 Mar; 33(9):1015-22. PubMed ID: 25667294
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab in recurrent high-grade pediatric gliomas.
Narayana A; Kunnakkat S; Chacko-Mathew J; Gardner S; Karajannis M; Raza S; Wisoff J; Weiner H; Harter D; Allen J
Neuro Oncol; 2010 Sep; 12(9):985-90. PubMed ID: 20363768
[TBL] [Abstract][Full Text] [Related]
19. Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.
Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Dastoli PA; Cavalheiro S; Caminada de Toledo SR
J Cancer Res Clin Oncol; 2022 Jan; 148(1):107-119. PubMed ID: 34626238
[TBL] [Abstract][Full Text] [Related]
20. SIOP-E-BTG and GPOH Guidelines for Diagnosis and Treatment of Children and Adolescents with Low Grade Glioma.
Gnekow AK; Kandels D; Tilburg CV; Azizi AA; Opocher E; Stokland T; Driever PH; Schouten-van Meeteren AYN; Thomale UW; Schuhmann MU; Czech T; Goodden JR; Warmuth-Metz M; Bison B; Avula S; Kortmann RD; Timmermann B; Pietsch T; Witt O
Klin Padiatr; 2019 May; 231(3):107-135. PubMed ID: 31108561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
